Biotech and Pharma

Trump’s Putin meeting crucial for oil prices, Berkshire Hathaway’s mystery solved, the case for rate cuts, and more news to start your day.

High profile investment managers were reporting their quarterly holdings on Thursday.

The U.K. list price for the largest dose version of Mounjaro is going up 170%.

Singapore hasn’t been suffering in the retreat from globalization, and yet the city-state is looking to sector diversification—financials, artificial intelligence, and pharmaceuticals—to reduce dependence on trade.

Antipathy from figures close to Trump toward mRNA technology, which underlies Moderna’s products and pipeline, has weighed on the company’s valuation.

Other company insiders purchased stock too, including Lilly’s executive vice president.

BigBear.ai tumbles as the AI company reports disappointing earnings and guidance, while Hanesbrands jumps following a report that Gildan Activewear was nearing a deal to acquire the underwear maker.

Coinbase and MicroStrategy rose along with the price of Bitcoin, while C3.ai and Monday.com sank on the heels of quarterly earnings.

Dr. Vinay Prasad, leader of the FDA division responsible for approving vaccines, is returning to the agency less than two weeks after leaving.

Shares of the biotech company have gone nowhere since 2015. That may be about to change.

Yeti shares soared after our 2019 bullish article, then backtracked. New products can keep the company on Wall Street’s radar.

Trade Desk crashed after the company named a new chief financial officer, Expedia rallied after an impressive earnings beat, and SoundHound jumped after what its CEO called the ‘strongest ever quarter.’

Many analysts trimmed price targets but remained bullish on Eli Lilly following Thursday’s stock selloff.

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the company’s broader business.

A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn’t enough to prevent a selloff.

Every corner of the sector is feeling the pain tis year. It’s well-positioned for a turnaround.

Lilly’s shot Zepbound has seized a commanding majority of U.S. obesity prescriptions.

The average effective tariff rate has climbed to more than 18%, six times where it started the year, according to the Yale Budget Lab.

Super Micro, AMD, and Snap stocks tumbled after quarterly earnings reports.

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying competition and a cratering stock price.

With elevated inflation, income investments that can keep up with the pace of rising prices are crucial.

Palantir rose after earnings blew past Wall Street estimates. Shares of Vertex Pharmaceuticals and Hims & Hers plummeted on weak quarterly results.

Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.